Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 280 of 280 results for coronavirus

  1. More people with rare genetic disorder eligible for nusinersen

    Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.

  2. Public consultation on updates to health technology evaluations manual

    A public consultation marking the first update to NICE's health technology evaluations manual is now open.

  3. Evidence Evusheld is effective in protecting vulnerable adults against variants lacking, as NICE announces new rapid update process for COVID-19 medicines

    NICE issues draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in some adults.

  4. More people could be treated out of hospital in the NHS's new respiratory hubs and virtual wards

    Consultation launched on draft guidance for the assessment and management of acute respiratory infections in people over 16

  5. People at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.

  6. Speaking with one language: How using a common data model might speed up decision making

    The European Health Data and Evidence Network (EHDEN) project could support faster patient access to innovative medicines in areas of unmet need.

  7. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  8. NICE welcomes life sciences review recommendations

    NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.

  9. Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia

    Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.

  10. Tackling health inequalities in children and young people

    We've updated our health inequalities web resource so that it maps NICE guidance to frameworks for children and young people.